Azemiglitazone

Azemiglitazone
Clinical data
Other names	Azemiglitazone potassium; MSDC-0602; MSDC-0602K
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 5-[[4-[2-(3-Methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;
CAS Number	1133819-87-0;
PubChem CID	25230266;
DrugBank	DB16028;
ChemSpider	32698412;
UNII	81MXZ6QOBM;
ChEMBL	ChEMBL4291468;
Chemical and physical data
Formula	C19H17NO5S
Molar mass	371.41 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3;
	InChI InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23); Key:YAUMOGALQJYOJQ-UHFFFAOYSA-N;

Azemiglitazone (MSDC-0602) is a novel insulin sensitizer designed to retain the effect of thiazolidinediones on mitochondrial pyruvate carriers with limited PPAR-gamma binding. It is hoped to have fewer adverse effects than the thiazolidinediones and is being developed by Cirius Therapeutics for type 2 diabetes and non-alcoholic fatty liver disease.^[1]^[2]^[3] It is formulated as its potassium salt, azemiglitazone potassium (MSDC-0602K).^{[citation needed]}

References

↑ Colca, Jerry R.; Lee, Bo Hyun; Iwashita, Julie S.; Dittrich, Howard C.; Harrison, Stephen A. (1 June 2020). "1090-P: MSDC-0602k, a New Oral Insulin Sensitizer in Insulin Resistant NASH Patients with and without Type 2 Diabetes (T2D)". Diabetes. 69 (Supplement_1) 1090-P. doi:10.2337/db20-1090-P. S2CID 225824217.
↑ Harrison, Stephen A.; Alkhouri, Naim; Davison, Beth A.; Sanyal, Arun; Edwards, Christopher; Colca, Jerry R.; Lee, Bo Hyun; Loomba, Rohit; Cusi, Kenneth; Kolterman, Orville; Cotter, Gad; Dittrich, Howard C. (April 2020). "Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study". Journal of Hepatology. 72 (4): 613–626. doi:10.1016/j.jhep.2019.10.023. PMID 31697972.
↑ Kamm, Dakota R.; Pyles, Kelly D.; Sharpe, Martin C.; Healy, Laura N.; Colca, Jerry R.; McCommis, Kyle S. (January 2021). "Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide". Journal of Biological Chemistry. 296 100807. doi:10.1016/j.jbc.2021.100807. PMC 8192871. PMID 34022222.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by adding missing information.